Non-Current Assets
Equity securities
Vertex Pharmaceuticals Equity securities increased by 22.9% to $20.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.6%, from $21.60M to $20.40M. Over 5 years (FY 2020 to FY 2025), Equity securities shows a downward trend with a -39.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ4 2019
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase reflects positive market performance of the underlying investments or additional capital deployment into equities.
Detailed definition
This represents the fair market value of the company's investment portfolio consisting of equity securities in other ent...
Peer comparison
Standard for companies with large corporate venture arms or significant treasury investment portfolios.
Metric ID:
ins_equity_securitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $154.10M | $218.76M | $230.90M | $155.30M | $71.10M | $122.80M | $116.80M | $148.10M | $52.60M | $46.40M | $46.00M | $43.40M | $30.60M | $33.40M | $36.60M | $21.60M | $27.90M | $9.40M | $16.60M | $20.40M |
| QoQ Change | — | +42.0% | +5.5% | -32.7% | -54.2% | +72.7% | -4.9% | +26.8% | -64.5% | -11.8% | -0.9% | -5.7% | -29.5% | +9.2% | +9.6% | -41.0% | +29.2% | -66.3% | +76.6% | +22.9% |
| YoY Change | — | — | — | — | -53.9% | -43.9% | -49.4% | -4.6% | -26.0% | -62.2% | -60.6% | -70.7% | -41.8% | -28.0% | -20.4% | -50.2% | -8.8% | -71.9% | -54.6% | -5.6% |
Range$9.40M – $230.90M
CAGR-34.7%
Avg YoY Growth-40.8%
Median YoY Growth-46.6%
Current Streak2 quarters growth
Equity securities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's equity securities?
- Vertex Pharmaceuticals (VRTX) reported equity securities of $20.40M in Q1 2026.
- How has Vertex Pharmaceuticals's equity securities changed year-over-year?
- Vertex Pharmaceuticals's equity securities decreased by 5.6% year-over-year, from $21.60M to $20.40M.
- What is the long-term trend for Vertex Pharmaceuticals's equity securities?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's equity securities has grown at a -39.0% compound annual growth rate (CAGR), from $195.78M to $16.60M.
- What does equity securities mean?
- The current market value of the company's stock investments in other businesses.